更多开发者作品
The Lancet
| 1. | [Comment] The time to address the antibiotic pipeline and access crisis is now | Manica Balasegaram, Kevin Outterson, John-Arne Røttingen | |
| 2. | [Comment] Changing the culture of blood culture | Sally Davies, Richard A Marfuggi, Rick A Bright, Steve Brozak, Michael Osterholm | |
| 3. | [Comment] Mpox global emergency: strengthening African leadership | Ibrahim Abubakar, Julius Lutwama, Catherine Kyobutungi, Osman Sankoh | |
| 4. | [Correspondence] An urgent case for measles vaccination in Gaza | Ronald Waldman, Robert Steinglass, Phillip Nieburg | |
| 5. | [Articles] Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050 | GBD 2021 Antimicrobial Resistance Collaborators | |
| 6. | [Comment] Global burden of antimicrobial resistance and forecasts to 2050 | Samuel Kariuki | |
| 7. | [Department of Error] Department of Error | | |
| 8. | [Comment] 177Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot | Joaquin Mateo, Amado J Zurita | |
| 9. | [Articles] 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial | Michael J Morris, Daniel Castellano, Ken Herrmann, Johann S de Bono, Neal D Shore, Kim N Chi, Michael Crosby, Josep M Piulats, Aude Fléchon, Xiao X Wei, Hakim Mahammedi, Guilhem Roubaud, Hana Študentová, James Nagarajah, Begoña Mellado, Álvaro Montesa-Pino, Euloge Kpamegan, Samson Ghebremariam, Teri N Kreisl, Celine Wilke, Katja Lehnhoff, Oliver Sartor, Karim Fizazi, PSMAfore Investigators | |
| 10. | [Articles] Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial | Domenica Lorusso, Yang Xiang, Kosei Hasegawa, Giovanni Scambia, Manuel Leiva, Pier Ramos-Elias, Alejandro Acevedo, Jakub Cvek, Leslie Randall, Andrea Juliana Pereira de Santana Gomes, Fernando Contreras Mejía, Limor Helpman, Hüseyin Akıllı, Jung-Yun Lee, Valeriya Saevets, Flora Zagouri, Lucy Gilbert, Jalid Sehouli, Ekkasit Tharavichitkul, Kristina Lindemann, Nicoletta Colombo, Chih-Long Chang, Marketa Bednarikova, Hong Zhu, Ana Oaknin, Melissa Christiaens, Edgar Petru, Tomoka Usami, Peng Liu, Karin Yamada, Sarper Toker, Stephen M Keefe, Sandro Pignata, Linda R Duska, ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators | |
| 11. | [Comment] Hope emerging in the locally advanced cervical cancer landscape | Christine Gennigens | |
| 12. | [Articles] Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial | Jonathan D Spicer, Marina C Garassino, Heather Wakelee, Moishe Liberman, Terufumi Kato, Masahiro Tsuboi, Se-Hoon Lee, Ke-Neng Chen, Christophe Dooms, Margarita Majem, Ekkehard Eigendorff, Gastón L Martinengo, Olivier Bylicki, Delvys Rodríguez-Abreu, Jamie E Chaft, Silvia Novello, Jing Yang, Ashwini Arunachalam, Steven M Keller, Ayman Samkari, Shugeng Gao, KEYNOTE-671 Investigators | |
| 13. | [Comment] Improved survival for patients with lung cancer treated with perioperative immunotherapy | Carolyn J Presley, Dwight H Owen | |
| 14. | [Correspondence] Mpox and breastmilk: for once, can we act in time? | Prince Imani-Musimwa, Mija Ververs | |
| 15. | [Correspondence] Childhood health and nutrition challenges in Sudan's conflict zones | Ibrahim Nagmeldin Hassan, Nagmeldin Abuassa, Mohamed Ibrahim | |
| 16. | [Articles] Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study | Toni K Choueiri, Laurence Albiges, Philippe Barthélémy, Roberto Iacovelli, Sheik Emambux, Javier Molina-Cerrillo, Benjamin Garmezy, Pedro Barata, Arnab Basu, Maria T Bourlon, Helen Moon, Raffaele Ratta, Rana R McKay, Alexander Chehrazi-Raffle, Hans Hammers, Daniel Y C Heng, Edgar Braendle, Kathryn E Beckermann, Bradley A McGregor, Robert J Motzer | |
| 17. | [Comment] Rechallenging with anti-PD-1 therapy in advanced renal cell carcinoma | Zachary A Yochum, David A Braun | |
| 18. | [Review] Lipoprotein(a) and cardiovascular disease | Børge G Nordestgaard, Anne Langsted | |
| 19. | [Comment] Long-term ill health in sepsis survivors: an ignored health-care challenge? | Abi Beane, Manu Shankar-Hari | |
| 20. | [Correspondence] The need for point-of-care tests for mpox | Ranu S Dhillon, Abraar Karan, Devabhaktuni Srikrishna, Jean-Vivien Mombouli | |
| 21. | [Comment] Addressing global gun violence: a Lancet Commission on Global Gun Violence and Health | Adnan A Hyder, Lorena Barberia, Lancet Commission on Global Gun Violence and Health | |
| 22. | [Comment] Primary health-care practices for deaf children should include early incorporation of a signed language | Wyatte C Hall, Julia L Hecht | |
| 23. | [Comment] Mexico's bold new law on adequate and sustainable nutrition | Elisa Pineda, Mauricio Hernández-F, Ana G Ortega-Avila, Alexandra Jones, Juan A Rivera | |
| 24. | [Comment] Priorities for sickle cell disease global research and implementation | Ambroise Wonkam, Nchangwi Syntia Munung, Aldiouma Guindo, Obiageli Nnodu | |
| 25. | [Comment] Non-communicable diseases: can implementation research change the game for policy and practice? | Kumanan Rasanathan, Phyllis Dako-Gyeke, Wanrudee Isaranuwatchai, Yodi Mahendradhata, Morven Roberts, Giulia Loffreda, Sarah Rylance, Bente Mikkelsen | |
| 26. | [Comment] Challenges in undertaking research in transplantation | GC Oniscu, K Rockell, DE Martin | |
| 27. | [Correspondence] A strong and independent Africa CDC would benefit the world | Nelson Aghogho Evaborhene | |
| 28. | [Department of Error] Department of Error | | |
| 29. | [Correspondence] Tracking COVID-19 responsibly | Rania Muhareb, Rita Giacaman | |
| 30. | [Correspondence] The truth about PHEICs | Johan Giesecke, STAG-IH | |
| 31. | [Review] Current approach of the axilla in patients with early-stage breast cancer | Eleftherios P Mamounas, Thorsten Kuehn, Emiel J T Rutgers, Gunter von Minckwitz | |
| 32. | [Series] The humanitarian system is not just broke, but broken: recommendations for future humanitarian action | Paul B Spiegel | |
| 33. | [Essay] My dying student | A Mark Clarfield | |
| 34. | [Comment] Women, power, and the cancer divide | Michelle Bachelet | |
| 35. | [World Report] 50 years of Medicare | Susan Jaffe | |
更新于 53 分钟前
近期历史最近 100 条记录
| 2024-09-21 | [Comment] The time to address the antibiotic pipeline and access crisis is now | Manica Balasegaram, Kevin Outterson, John-Arne Røttingen | |
| 2024-09-21 | [Comment] Changing the culture of blood culture | Sally Davies, Richard A Marfuggi, Rick A Bright, Steve Brozak, Michael Osterholm | |
| 2024-09-21 | [Comment] Mpox global emergency: strengthening African leadership | Ibrahim Abubakar, Julius Lutwama, Catherine Kyobutungi, Osman Sankoh | |
| 2024-09-21 | [Correspondence] An urgent case for measles vaccination in Gaza | Ronald Waldman, Robert Steinglass, Phillip Nieburg | |
| 2024-09-17 | [Articles] Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050 | GBD 2021 Antimicrobial Resistance Collaborators | |
| 2024-09-17 | [Comment] Global burden of antimicrobial resistance and forecasts to 2050 | Samuel Kariuki | |
| 2024-09-17 | [Department of Error] Department of Error | | |
| 2024-09-15 | [Articles] 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial | Michael J Morris, Daniel Castellano, Ken Herrmann, Johann S de Bono, Neal D Shore, Kim N Chi, Michael Crosby, Josep M Piulats, Aude Fléchon, Xiao X Wei, Hakim Mahammedi, Guilhem Roubaud, Hana Študentová, James Nagarajah, Begoña Mellado, Álvaro Montesa-Pin | |
| 2024-09-15 | [Comment] 177Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot | Joaquin Mateo, Amado J Zurita | |
| 2024-09-14 | [Articles] Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, p | Domenica Lorusso, Yang Xiang, Kosei Hasegawa, Giovanni Scambia, Manuel Leiva, Pier Ramos-Elias, Alejandro Acevedo, Jakub Cvek, Leslie Randall, Andrea Juliana Pereira de Santana Gomes, Fernando Contreras Mejía, Limor Helpman, Hüseyin Akıllı, Jung-Yun Lee, | |
| 2024-09-14 | [Comment] Hope emerging in the locally advanced cervical cancer landscape | Christine Gennigens | |
| 2024-09-14 | [Articles] Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, p | Jonathan D Spicer, Marina C Garassino, Heather Wakelee, Moishe Liberman, Terufumi Kato, Masahiro Tsuboi, Se-Hoon Lee, Ke-Neng Chen, Christophe Dooms, Margarita Majem, Ekkehard Eigendorff, Gastón L Martinengo, Olivier Bylicki, Delvys Rodríguez-Abreu, Jamie | |
| 2024-09-14 | [Comment] Improved survival for patients with lung cancer treated with perioperative immunotherapy | Carolyn J Presley, Dwight H Owen | |
| 2024-09-14 | [Correspondence] Mpox and breastmilk: for once, can we act in time? | Prince Imani-Musimwa, Mija Ververs | |
| 2024-09-14 | [Correspondence] Childhood health and nutrition challenges in Sudan's conflict zones | Ibrahim Nagmeldin Hassan, Nagmeldin Abuassa, Mohamed Ibrahim | |
| 2024-09-13 | [Articles] Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study | Toni K Choueiri, Laurence Albiges, Philippe Barthélémy, Roberto Iacovelli, Sheik Emambux, Javier Molina-Cerrillo, Benjamin Garmezy, Pedro Barata, Arnab Basu, Maria T Bourlon, Helen Moon, Raffaele Ratta, Rana R McKay, Alexander Chehrazi-Raffle, Hans Hammer | |
| 2024-09-13 | [Comment] Rechallenging with anti-PD-1 therapy in advanced renal cell carcinoma | Zachary A Yochum, David A Braun | |
| 2024-09-13 | [Review] Lipoprotein(a) and cardiovascular disease | Børge G Nordestgaard, Anne Langsted | |
| 2024-09-13 | [Department of Error] Department of Error | | |
| 2024-09-12 | [Comment] Long-term ill health in sepsis survivors: an ignored health-care challenge? | Abi Beane, Manu Shankar-Hari | |
| 2024-09-11 | [Articles] Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial | Richard M Bergenstal, Ruth S Weinstock, Chantal Mathieu, Yukiko Onishi, Vishali Vijayanagaram, Michelle L Katz, Molly C Carr, Annette M Chang | |
| 2024-09-10 | [Correspondence] A call for global solidarity and rapid action to control mpox | Jean B Nachega, Jean‑Jacques Muyembe‑Tamfum, Francine Ntoumi, Placide Mbala‑Kingebeni, Alimuddin Zumla | |
| 2024-09-10 | [Comment] Antimicrobial resistance at a crossroads: the cost of inaction | Michael Craig, Daniel Jernigan, Kayla Laserson, Stefanie McBride, Jessica Fairbanks, Dawn Sievert, Paige A Armstrong, Heather Ewing Ogle, Howard Zucker | |
| 2024-09-09 | [Series] Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children | Clint Pecenka, Erin Sparrow, Daniel R Feikin, Padmini Srikantiah, Delese Mimi Darko, Eric Karikari-Boateng, Ranju Baral, Carla Vizzotti, Analia Rearte, Rose Jalang'o, Jessica A Fleming, Federico Martinón-Torres, Ruth A Karron | |
| 2024-09-09 | [Series] Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies | Natalie I Mazur, Mauricio T Caballero, Marta C Nunes | |
| 2024-09-07 | [Correspondence] The need for point-of-care tests for mpox | Ranu S Dhillon, Abraar Karan, Devabhaktuni Srikrishna, Jean-Vivien Mombouli | |
| 2024-09-06 | [Comment] Advancing the economics of health for all | Mariana Mazzucato, Tedros Adhanom Ghebreyesus | |
| 2024-09-04 | [Correspondence] A crisis of safety: female health-care workers in India need reforms | Gururaj Arakeri, Vishal Rao, Shankargouda Patil | |
| 2024-09-04 | [Comment] Addressing global gun violence: a Lancet Commission on Global Gun Violence and Health | Adnan A Hyder, Lorena Barberia, Lancet Commission on Global Gun Violence and Health | |
| 2024-09-03 | [Department of Error] Department of Error | | |
| 2024-09-03 | [Correspondence] Mpox in eastern Democratic Republic of the Congo: challenges and prospects for vaccination | Harry César Kayembe Ntumba, Bien-Aimé Makasa Mandja | |
| 2024-09-02 | [Comment] Optical coherence tomography imaging for complex percutaneous coronary intervention | Mamas A Mamas, Gary S Mintz | |
| 2024-09-02 | [Comment] How feasible is a cage-free solution for de novo coronary artery disease? | Margaret B McEntegart, Ajay J Kirtane | |
| 2024-09-02 | [Articles] Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea | Sung-Jin Hong, Seung-Jun Lee, Sang-Hyup Lee, Jong-Young Lee, Deok-Kyu Cho, Jin Won Kim, Sang Min Kim, Seung-Ho Hur, Jung Ho Heo, Ji-Yong Jang, Jin Sin Koh, Hoyoun Won, Jun-Won Lee, Soon Jun Hong, Dong-Kie Kim, Jeong Cheon Choe, Jin Bae Lee, Soo-Joong Kim, | |
| 2024-09-02 | [Articles] Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial | Chao Gao, Xingqiang He, Fan Ouyang, Zhihui Zhang, Guidong Shen, Mingxing Wu, Ping Yang, Likun Ma, Feng Yang, Zheng Ji, Hua Wang, Yanqing Wu, Zhenfei Fang, Hong Jiang, Shangyu Wen, Yi Liu, Fei Li, Jingyu Zhou, Bin Zhu, Yunpeng Liu, Ruining Zhang, Tingting | |
| 2024-09-02 | [Articles] Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up | Holger Thiele, Jacob E Møller, Jose P S Henriques, Margriet Bogerd, Melchior Seyfarth, Daniel Burkhoff, Petr Ostadal, Richard Rokyta, Jan Belohlavek, Steffen Massberg, Marcus Flather, Matthias Hochadel, Steffen Schneider, Steffen Desch, Anne Freund, Hans | |
| 2024-09-02 | [Comment] Optimal patient and mechanical circulatory support device selection in acute myocardial infarction cardiogenic shock | Jacob C Jentzer, Benjamin Hibbert | |
| 2024-09-01 | [Articles] Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis | Pardeep S Jhund, Atefeh Talebi, Alasdair D Henderson, Brian L Claggett, Muthiah Vaduganathan, Akshay S Desai, Carolyn S P Lam, Bertram Pitt, Michele Senni, Sanjiv J Shah, Adriaan A Voors, Faiez Zannad, Scott D Solomon, John J V McMurray | |
| 2024-09-01 | [Comment] Mineralocorticoid receptor antagonists for every patient with heart failure | Frans H Rutten, Amy Groenewegen | |
| 2024-08-31 | [Articles] De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials | Marco Valgimigli, Sung-Jin Hong, Felice Gragnano, Konstantina Chalkou, Anna Franzone, Bruno R da Costa, Usman Baber, Byeong-Keuk Kim, Yangsoo Jang, Shao-Liang Chen, Gregg W Stone, Joo-Yong Hahn, Stephan Windecker, Michael C Gibson, Young Bin Song, Zhen Ge | |
| 2024-08-31 | [Comment] Is this the conclusive evidence for ticagrelor monotherapy in acute coronary syndromes? | Giulio G Stefanini, Angelo Oliva | |
| 2024-08-31 | [Correspondence] Mpox threat: Pakistan must act now | Saad Javed, Nimirta Sahitia, Eesha Yaqoob | |
| 2024-08-31 | [Correspondence] Enhancing mpox response in Africa with implementation science | Abdu A Adamu, Joseph Okeibunor, Reena H Doshi, Charles S Wiysonge | |
| 2024-08-30 | [Comment] GLP-1 receptor agonists in heart failure: how far to expand use? | Camilla Hage | |
| 2024-08-30 | [Articles] Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials | Mikhail N Kosiborod, John Deanfield, Richard Pratley, Barry A Borlaug, Javed Butler, Melanie J Davies, Scott S Emerson, Steven E Kahn, Dalane W Kitzman, Ildiko Lingvay, Kenneth W Mahaffey, Mark C Petrie, Jorge Plutzky, Søren Rasmussen, Cecilia Rönnbäck, S | |
| 2024-08-30 | [Correspondence] Far-right riots in the UK: the culmination of years of rhetoric and policies | Yamina Boukari, Delan Devakumar | |
| 2024-08-30 | [Correspondence] 6 months on: South Korean medical students still on leave | Dongju Shin, Dong-Jin Shin | |
| 2024-08-29 | [Seminar] Primary biliary cholangitis | Atsushi Tanaka, Xiong Ma, Atsushi Takahashi, John M Vierling | |
| 2024-08-29 | [Comment] Primary health-care practices for deaf children should include early incorporation of a signed language | Wyatte C Hall, Julia L Hecht | |
| 2024-08-27 | [Correspondence] Bangladesh protests: law enforcement and public health crisis | Md Abu Bakkar Siddik | |
| 2024-08-24 | [Correspondence] The health of migrants at the intersection of mpox and HIV | Archibong Edem Bassey | |
| 2024-08-23 | [Correspondence] Strengthening community resilience: lessons from COVID-19 for mpox prevention | Francesco Branda, Giancarlo Ceccarelli, Massimo Ciccozzi, Fabio Scarpa | |
| 2024-08-22 | [Seminar] X-linked hypophosphataemia | Peter Kamenický, Karine Briot, Craig F Munns, Agnès Linglart | |
| 2024-08-19 | [Comment] The mpox emergency and the role of Gavi | Sania Nishtar | |
| 2024-08-19 | [Editorial] Mpox: the need for a coordinated international response | The Lancet | |
| 2024-08-17 | [Seminar] Obesity in adults | Ildiko Lingvay, Ricardo V Cohen, Carel W le Roux, Priya Sumithran | |
| 2024-08-17 | [Viewpoint] International coverage of GLP-1 receptor agonists: a review and ethical analysis of discordant approaches | Johan L Dellgren, Govind Persad, Ezekiel J Emanuel | |
| 2024-08-17 | [Correspondence] Human rights considerations are key when choosing a conference location | Shelagh B Coutts, Nikola Sprigg | |
| 2024-08-17 | [Comment] Transforming humanitarian aid through lived experience | Kemish Kenneth Alier | |
| 2024-08-15 | [Comment] The Glasgow Coma Scale at 50: looking back and forward | Geoffrey T Manley, Andrew IR Maas | |
| 2024-08-13 | [Comment] Nature-based solutions are essential for climate and health action | Neil M Vora, Shweta Narayan, Aggrey Aluso, Camila I Donatti, Omnia El Omrani, Lee Hannah, Jemilah Mahmood, Nicaise Ndembi, Mariana M Vale, Elizabeth Willetts | |
| 2024-08-09 | [Comment] Integrating patient and public involvement and engagement in translational medicine | Karen L Shaw, Melanie J Calvert, Persephone Borrow, Evelyn Chakera, Ronjon Chakraverty, Sarah E Hughes, Foram Khatsuria, Francesca A M Kinsella, Christel McMullan, Julie Richardson-Abraham, Vlada Yarosh, Olalekan Lee Aiyegbusi | |
| 2024-08-07 | [Review] New promises and challenges in the treatment of advanced non-small-cell lung cancer | May-Lucie Meyer, Bailey G Fitzgerald, Luis Paz-Ares, Federico Cappuzzo, Pasi A Jänne, Solange Peters, Fred R Hirsch | |
| 2024-08-02 | [Seminar] Acute liver failure | Rakhi Maiwall, Anand V Kulkarni, Juan Pablo Arab, Salvatore Piano | |
| 2024-08-01 | [Comment] Sjögren's disease: a new era for clinical trials? | Serena Colafrancesco, Roberta Priori | |
| 2024-08-01 | [Review] Long COVID: a clinical update | Trisha Greenhalgh, Manoj Sivan, Alice Perlowski, Janko Ž Nikolich | |
| 2024-08-01 | [Articles] Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study | Alwin Krämer, Tilmann Bochtler, Chantal Pauli, Kai-Keen Shiu, Natalie Cook, Juliana Janoski de Menezes, Roberto A Pazo-Cid, Ferran Losa, Debbie GJ Robbrecht, Jiří Tomášek, Cagatay Arslan, Mustafa Özgüroğlu, Michael Stahl, Frédéric Bigot, Sun Young Kim, Yo | |
| 2024-08-01 | [Comment] Molecular guided therapies: a practice-changing step forward in cancer of unknown primary management | Elie Rassy, F Anthony Greco, Nicholas Pavlidis | |
| 2024-08-01 | [Articles] Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study | Benjamin A Fisher, Xavier Mariette, Athena Papas, Thomas Grader-Beck, Hendrika Bootsma, Wan-Fai Ng, P L A van Daele, Stephanie Finzel, Ghaith Noaiseh, Sergio Elgueta, Josef Hermann, Sara S McCoy, Esen Akpek, Arthur Bookman, Monika Sopala, Michela Montecch | |
| 2024-08-01 | [The Lancet Commissions] Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission | Gill Livingston, Jonathan Huntley, Kathy Y Liu, Sergi G Costafreda, Geir Selbæk, Suvarna Alladi, David Ames, Sube Banerjee, Alistair Burns, Carol Brayne, Nick C Fox, Cleusa P Ferri, Laura N Gitlin, Robert Howard, Helen C Kales, Mika Kivimäki, Eric B Larso | |
| 2024-08-01 | [Comment] Pivotal points in the science of dementia risk reduction | Miia Kivipelto, Francesca Mangialasche, Kaarin J Anstey | |
| 2024-07-26 | [Articles] Activity limitations, use of assistive devices, and mortality and clinical events in 25 high-income, middle-income, and low-income countries: an analysis of the PURE study | Raed A Joundi, Bo Hu, Sumathy Rangarajan, Darryl P Leong, Shofiqul Islam, Eric E Smith, Erkin Mirrakhimov, Pamela Seron, Khalid F Alhabib, Batyrbek Assembekov, Jephat Chifamba, Rita Yusuf, Rasha Khatib, Camilo Felix, Afzalhussein Yusufali, Noushin Mohamma | |
| 2024-07-26 | [Comment] A novel treatment approach for atopic dermatitis | Patrick M Brunner | |
| 2024-07-26 | [Viewpoint] Differentiating mortality risk of individual infants and children to improve survival: opportunity for impact | James A Berkley, Judd L Walson, Rajiv Bahl, Nigel Rollins | |
| 2024-07-26 | [Seminar] Chronic lymphocytic leukaemia | Nitin Jain, William G Wierda, Susan O'Brien | |
| 2024-07-26 | [Comment] Global disparities in activity limitations and use of assistive devices | Ekaterina Zotcheva, Ellen Melbye Langballe | |
| 2024-07-26 | [Comment] Mexico's bold new law on adequate and sustainable nutrition | Elisa Pineda, Mauricio Hernández-F, Ana G Ortega-Avila, Alexandra Jones, Juan A Rivera | |
| 2024-07-25 | [Comment] Many crises, one call to action: advancing gender equality in health in response to polycrises | Rajat Khosla, Gita Sen, Tedros Adhanom Ghebreyesus, Winnie Byanyima, Sima Bahous, Debora Diniz, Sara Hossain, Natalia Kanem, Ulrika Karlsson, Laura Laski, Dina Mired, Catherine Russell, Tlaleng Mofokeng, Achim Steiner, Volker Türk, Johanna Riha | |
| 2024-07-25 | [Articles] Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials | Jonathan I Silverberg, Andreas Wollenberg, Adam Reich, Diamant Thaçi, Franz J Legat, Kim A Papp, Linda Stein Gold, Jean-David Bouaziz, Andrew E Pink, José Manuel Carrascosa, Barbara Rewerska, Jacek C Szepietowski, Dorota Krasowska, Blanka Havlíčková, Moni | |
| 2024-07-25 | [Comment] Realigning the physical activity research agenda for population health, equity, and wellbeing | Ding Ding, Sebastien Chastin, Deborah Salvo, Tracy Nau, Klaus Gebel, Miguel Adriano Sanchez-Lastra, Mengyun Luo, Inacio Crochemore-Silva, Ulf Ekelund, Adrian Bauman | |
| 2024-07-24 | [Perspectives] Mandy Cohen: public health advocate and Director of the US CDC | Susan Jaffe | |
| 2024-07-23 | [Perspectives] Rochelle Burgess: disrupting the status quo in global mental health | Rachael Davies | |
| 2024-07-19 | [Seminar] Renal cell carcinoma | Matthew Young, Francesca Jackson-Spence, Luis Beltran, Elizabeth Day, Christina Suarez, Axel Bex, Thomas Powles, Bernadett Szabados | |
| 2024-07-19 | [Articles] Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials | Robert Bissonnette, Richard B Warren, Andreas Pinter, Tove Agner, Melinda Gooderham, Marie L A Schuttelaar, Marie-Noëlle Crépy, Luca Stingeni, Esther Serra-Baldrich, Keith Baranowski, Sofie Korn, Merle Kurvits, Ursula Plohberger, Natacha Strange Vest, Sib | |
| 2024-07-19 | [Comment] Hands-on: a novel JAK inhibitor for the treatment of chronic hand eczema | Yael Renert-Yuval, Emma Guttman-Yassky | |
| 2024-07-16 | [Perspectives] Kathleen Maletic Neuzil: new Fogarty International Center leader | Udani Samarasekera | |
| 2024-07-13 | [Comment] Unlocking the power of NHS research: a priority for the new UK Government | Andrew Morris | |
| 2024-07-12 | [Therapeutics] Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment | Torsten Zuberbier, Luis Felipe Ensina, Ana Giménez-Arnau, Clive Grattan, Emek Kocatürk, Kanokvalai Kulthanan, Pavel Kolkhir, Marcus Maurer | |
| 2024-07-12 | [Comment] Transparent and complete reporting of surrogate endpoints in trials: the SPIRIT-Surrogate and CONSORT-Surrogate extensions | Anthony Muchai Manyara, Oriana Ciani, Rod S Taylor, SPIRIT-Surrogate and CONSORT-Surrogate Project team and Consensus Group | |
| 2024-07-11 | [Comment] Priorities for sickle cell disease global research and implementation | Ambroise Wonkam, Nchangwi Syntia Munung, Aldiouma Guindo, Obiageli Nnodu | |
| 2024-07-10 | [Department of Error] Department of Error | | |
| 2024-07-10 | [Comment] The UK Government's mandate for change must prioritise transformation of the public's health | Kevin Fenton, Greg Fell, William Roberts, Margaret Rae | |
| 2024-07-10 | [Comment] CD22 CAR T-cell therapy: new hope for patients with large B-cell lymphoma | Maria-Luisa Schubert, Peter Dreger | |
| 2024-07-10 | [Articles] CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study | Matthew J Frank, John H Baird, Anne Marijn Kramer, Hrishikesh K Srinagesh, Shabnum Patel, Annie Kathleen Brown, Jean S Oak, Sheren F Younes, Yasodha Natkunam, Mark P Hamilton, Yi-Jiun Su, Neha Agarwal, Harshini Chinnasamy, Emily Egeler, Sharon Mavroukakis | |
| 2024-07-09 | [Comment] Self-guided digital acceptance and commitment therapy as a treatment option for fibromyalgia | Guilherme Torres Vilarino | |
| 2024-07-09 | [Articles] Self-guided digital behavioural therapy versus active control for fibromyalgia (PROSPER-FM): a phase 3, multicentre, randomised controlled trial | R Michael Gendreau, Lance M McCracken, David A Williams, Juan V Luciano, Yifei Dai, Nicolette Vega, Zunera Ghalib, Kristen Guthrie, Allison C Kraus, Michael J Rosenbluth, Ben Vaughn, Jennifer M Zomnir, Dana Reddy, Andrea L Chadwick, Daniel J Clauw, Lesley | |
| 2024-07-06 | [Correspondence] Counting the dead in Gaza: difficult but essential | Rasha Khatib, Martin McKee, Salim Yusuf | |
| 2024-07-05 | [Comment] Physician associates in the UK and the role of the doctor | Jessamy Bagenal | |
| 2024-07-04 | [Articles] Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial | Peter Borchmann, Justin Ferdinandus, Gundolf Schneider, Alden Moccia, Richard Greil, Mark Hertzberg, Valdete Schaub, Andreas Hüttmann, Felix Keil, Judith Dierlamm, Mathias Hänel, Urban Novak, Julia Meissner, Andreas Zimmermann, Stephan Mathas, Josée M Zij | |
| 2024-07-04 | [Comment] The CONCORD–Lancet Global Commission on Cancer | Claudia Allemani, Gulnar Azevedo e Silva, Prashant Mathur, Michel P Coleman | |
匿名用户只展示最新 100 条榜单历史，更多历史数据请登录后查看，支持时光机按天筛选
Sponsors
